Literature DB >> 15095785

The role of phosphatidylserine in recognition and removal of erythrocytes.

F A Kuypers1, K de Jong.   

Abstract

During the time that erythrocytes (RBC) spend in the circulation, a series of progressive events take place that lead to their removal and determine their apparent aging and limited survival. In addition, a fraction of RBC precursors will be removed during erythropoiesis by apoptotic processes, often described as "ineffective erythropoiesis". Both will determine the survival of erythroid cells and play an important role in red cell pathology, including hemoglobinopathies and red cell membrane disorders. The loss of phospholipid asymmetry, and the exposure of phosphatidylserine (PS) on the surface of plasma membranes may be a general trigger by which cells, including aging RBC and apoptotic cells, are removed. Oxidant stress and inactivation of the system that maintains phospholipid asymmetry play a central role in the events that will lead to PS exposure, death and removal.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15095785

Source DB:  PubMed          Journal:  Cell Mol Biol (Noisy-le-grand)        ISSN: 0145-5680            Impact factor:   1.770


  42 in total

1.  A role for activated endothelial cells in red blood cell clearance: implications for vasopathology.

Authors:  Marcel H A M Fens; Richard van Wijk; Grietje Andringa; Karlijn L van Rooijen; Hilde M Dijstelbloem; Jan T Rasmussen; Karen M K de Vooght; Raymond M Schiffelers; Carlo A J M Gaillard; Wouter W van Solinge
Journal:  Haematologica       Date:  2011-11-18       Impact factor: 9.941

Review 2.  β-thalassemia intermedia: a clinical perspective.

Authors:  Khaled M Musallam; Ali T Taher; Eliezer A Rachmilewitz
Journal:  Cold Spring Harb Perspect Med       Date:  2012-07       Impact factor: 6.915

3.  Increased cation conductance in human erythrocytes artificially aged by glycation.

Authors:  Yuliya V Kucherenko; Shefalee K Bhavsar; Valentin I Grischenko; Uwe R Fischer; Stephan M Huber; Florian Lang
Journal:  J Membr Biol       Date:  2010-06-06       Impact factor: 1.843

4.  Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

Authors:  Mark T Gladwin; Gregory J Kato
Journal:  Haematologica       Date:  2008-01       Impact factor: 9.941

Review 5.  Red blood cell deformability during storage: towards functional proteomics and metabolomics in the Blood Bank.

Authors:  Judith C A Cluitmans; Max R Hardeman; Sip Dinkla; Roland Brock; Giel J C G M Bosman
Journal:  Blood Transfus       Date:  2012-05       Impact factor: 3.443

6.  Phosphatidylserine exposure on stored red blood cells as a parameter for donor-dependent variation in product quality.

Authors:  Sip Dinkla; Malou Peppelman; Jori Van Der Raadt; Femke Atsma; Vera M J Novotný; Marian G J Van Kraaij; Irma Joosten; Giel J C G M Bosman
Journal:  Blood Transfus       Date:  2013-10-03       Impact factor: 3.443

7.  Release of FGF1 and p40 synaptotagmin 1 correlates with their membrane destabilizing ability.

Authors:  Irene Graziani; Cinzia Bagalá; Maria Duarte; Raffaella Soldi; Vihren Kolev; Francesca Tarantini; Thallapuranam Krishnaswamy Suresh Kumar; Andrew Doyle; David Neivandt; Chin Yu; Thomas Maciag; Igor Prudovsky
Journal:  Biochem Biophys Res Commun       Date:  2006-08-14       Impact factor: 3.575

8.  Impact of developmental lead exposure on splenic factors.

Authors:  Jane Kasten-Jolly; Yong Heo; David A Lawrence
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-11       Impact factor: 4.219

Review 9.  Role of the hemostatic system on sickle cell disease pathophysiology and potential therapeutics.

Authors:  Zahra Pakbaz; Ted Wun
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

10.  Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice.

Authors:  Trisha Dasgupta; Mary E Fabry; Dhananjay K Kaul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-12-09       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.